TransMedics Group, Inc. (TMDX) EV/Sales Ratio: 5.12x
Is TransMedics Group, Inc.’s EV/Sales ratio high or low?
TransMedics Group, Inc.'s EV/Sales ratio of 5.12x is 69% below its 5-year average of 16.32x, near the low end of its 5-year range (4.16x–37.86x).
As of Saturday, June 20, 2026. 43.33% below its 12-month average of 9.04x.
TMDX EV/Sales Ratio Chart
TMDX Average EV/Sales Ratio Chart
TMDX Current vs Average EV/Sales Ratio Chart
TMDX EV/Sales Ratio Metrics
EV/SALES RATIO
5.12x
EV/SALES RATIO AVG TTM
9.04x
EV/SALES RATIO AVG 3Y
10.89x
EV/SALES RATIO AVG 5Y
16.32x
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-43.33%
CURRENT VS 3Y AVG
-53.00%
CURRENT VS 5Y AVG
-68.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TMDX Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.72B | 5.12x | 9.04x | 10.89x | 16.32x |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.07B | 1.14x | 1.26x | 1.71x | 2.17x |
| 23andMe Holding Co. (ME)vs › | $15.31M | 0.02x | 0.35x | 0.71x | 3.53x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 3.28x | 3.42x | 3.67x | 4.56x |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 3.80x | 4.63x | 4.20x | 4.24x |
| Tempus AI, Inc. (TEM)vs › | $8.87B | 7.25x | 11.33x | 12.15x | 12.15x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 2.96x | 2.80x | 3.02x | 3.78x |
| Baxter International Inc. (BAX)vs › | $10.27B | 1.58x | 1.71x | 2.16x | 2.63x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 0.25x | 0.26x | 0.37x | 0.45x |
| Revvity, Inc. (RVTY)vs › | $11.16B | 4.71x | 4.79x | 5.55x | 5.57x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
TransMedics Group, Inc. EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
TransMedics Group, Inc. EV/Sales Ratio FAQ
- What is the EV/Sales ratio for TransMedics Group, Inc. (TMDX)?
- The EV/Sales ratio for TMDX stock is 5.12x.
- Is TransMedics Group, Inc.'s EV/Sales ratio high or low?
- TransMedics Group, Inc.'s EV/Sales ratio of 5.12x is 69% below its 5-year average of 16.32x, near the low end of its 5-year range (4.16x–37.86x).
- What is the TTM average EV/Sales ratio for TransMedics Group, Inc. (TMDX)?
- The TTM average EV/Sales ratio for TMDX stock is 9.04x.
- What is the 3Y average EV/Sales ratio for TransMedics Group, Inc. (TMDX)?
- The 3Y average EV/Sales ratio for TMDX stock is 10.89x.
- What is the 5Y average EV/Sales ratio for TransMedics Group, Inc. (TMDX)?
- The 5Y average EV/Sales ratio for TMDX stock is 16.32x.
TransMedics Group, Inc. EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-18 | 5.12x |
| 2026-06-17 | 4.80x |
| 2026-06-16 | 4.95x |
| 2026-06-15 | 4.93x |
| 2026-06-12 | 4.78x |
| 2026-06-11 | 4.82x |
| 2026-06-10 | 4.89x |
| 2026-06-09 | 4.86x |
| 2026-06-08 | 4.68x |
| 2026-06-05 | 4.58x |
| 2026-06-04 | 4.69x |
| 2026-06-03 | 4.60x |
| 2026-06-02 | 4.53x |
| 2026-06-01 | 4.48x |
| 2026-05-29 | 4.46x |
| 2026-05-28 | 4.49x |
| 2026-05-27 | 4.62x |
| 2026-05-26 | 4.64x |
| 2026-05-22 | 4.56x |
| 2026-05-21 | 4.55x |
| 2026-05-20 | 4.50x |
| 2026-05-19 | 4.40x |
| 2026-05-18 | 4.52x |
| 2026-05-15 | 4.23x |
| 2026-05-14 | 4.16x |
| 2026-05-13 | 4.28x |
| 2026-05-12 | 4.27x |
| 2026-05-11 | 4.29x |
| 2026-05-08 | 4.49x |
| 2026-05-07 | 4.78x |
| 2026-05-06 | 4.78x |
| 2026-05-05 | 6.03x |
| 2026-05-04 | 6.53x |
| 2026-05-01 | 6.73x |
| 2026-04-30 | 6.78x |
| 2026-04-29 | 6.63x |
| 2026-04-28 | 6.81x |
| 2026-04-27 | 7.28x |
| 2026-04-24 | 7.47x |
| 2026-04-23 | 7.62x |
| 2026-04-22 | 7.72x |
| 2026-04-21 | 7.33x |
| 2026-04-20 | 7.62x |
| 2026-04-17 | 7.80x |
| 2026-04-16 | 7.35x |
| 2026-04-15 | 7.82x |
| 2026-04-14 | 7.79x |
| 2026-04-13 | 7.63x |
| 2026-04-10 | 7.67x |
| 2026-04-09 | 7.35x |
| 2026-04-08 | 7.36x |
| 2026-04-07 | 7.22x |
| 2026-04-06 | 7.05x |
| 2026-04-02 | 6.78x |
| 2026-04-01 | 6.76x |
| 2026-03-31 | 6.69x |
| 2026-03-30 | 6.34x |
| 2026-03-27 | 6.66x |
| 2026-03-26 | 6.88x |
| 2026-03-25 | 7.08x |
| 2026-03-24 | 7.33x |
| 2026-03-23 | 7.55x |
| 2026-03-20 | 7.67x |
| 2026-03-19 | 7.66x |
| 2026-03-18 | 7.62x |
| 2026-03-17 | 8.40x |
| 2026-03-16 | 8.40x |
| 2026-03-13 | 8.32x |
| 2026-03-12 | 8.17x |
| 2026-03-11 | 8.69x |
| 2026-03-10 | 8.81x |
| 2026-03-09 | 9.08x |
| 2026-03-06 | 8.73x |
| 2026-03-05 | 9.44x |
| 2026-03-04 | 9.95x |
| 2026-03-03 | 9.97x |
| 2026-03-02 | 9.91x |
| 2026-02-27 | 9.79x |
| 2026-02-26 | 9.07x |
| 2026-02-25 | 8.88x |
| 2026-02-24 | 9.28x |
| 2026-02-23 | 9.78x |
| 2026-02-20 | 9.75x |
| 2026-02-19 | 9.65x |
| 2026-02-18 | 9.84x |
| 2026-02-17 | 9.72x |
| 2026-02-13 | 9.44x |
| 2026-02-12 | 9.34x |
| 2026-02-11 | 9.68x |
| 2026-02-10 | 10.12x |
| 2026-02-09 | 9.90x |
| 2026-02-06 | 9.81x |
| 2026-02-05 | 9.42x |
| 2026-02-04 | 9.47x |
| 2026-02-03 | 9.86x |
| 2026-02-02 | 9.73x |
| 2026-01-30 | 9.73x |
| 2026-01-29 | 10.09x |
| 2026-01-28 | 10.24x |
| 2026-01-27 | 10.06x |
| 2026-01-26 | 10.12x |
| 2026-01-23 | 9.83x |
| 2026-01-22 | 10.03x |
| 2026-01-21 | 9.72x |
| 2026-01-20 | 10.31x |
| 2026-01-16 | 10.41x |
| 2026-01-15 | 10.43x |
| 2026-01-14 | 10.31x |
| 2026-01-13 | 10.36x |
| 2026-01-12 | 9.78x |
| 2026-01-09 | 9.96x |
| 2026-01-08 | 9.99x |
| 2026-01-07 | 9.97x |
| 2026-01-06 | 9.64x |
| 2026-01-05 | 9.18x |
| 2026-01-02 | 8.92x |
| 2025-12-31 | 8.85x |
| 2025-12-30 | 8.87x |
| 2025-12-29 | 8.95x |
| 2025-12-26 | 9.03x |
| 2025-12-24 | 9.23x |
| 2025-12-23 | 9.32x |
| 2025-12-22 | 9.40x |
| 2025-12-19 | 9.28x |
| 2025-12-18 | 8.80x |
| 2025-12-17 | 8.87x |
| 2025-12-16 | 9.09x |
| 2025-12-15 | 8.95x |
| 2025-12-12 | 9.22x |
| 2025-12-11 | 9.28x |
| 2025-12-10 | 9.53x |
| 2025-12-09 | 9.79x |
| 2025-12-08 | 9.92x |
| 2025-12-05 | 9.92x |
| 2025-12-04 | 10.07x |
| 2025-12-03 | 10.17x |
| 2025-12-02 | 10.29x |
| 2025-12-01 | 10.92x |
| 2025-11-28 | 10.62x |
| 2025-11-26 | 10.58x |
| 2025-11-25 | 10.60x |
| 2025-11-24 | 10.18x |
| 2025-11-21 | 9.51x |
| 2025-11-20 | 9.00x |
| 2025-11-19 | 9.70x |
| 2025-11-18 | 8.52x |
| 2025-11-17 | 8.25x |
| 2025-11-14 | 8.37x |
| 2025-11-13 | 8.41x |
| 2025-11-12 | 8.67x |
| 2025-11-11 | 8.88x |
| 2025-11-10 | 8.90x |
| 2025-11-07 | 8.67x |
| 2025-11-06 | 9.09x |
| 2025-11-05 | 9.05x |
| 2025-11-04 | 8.89x |
| 2025-11-03 | 9.07x |
| 2025-10-31 | 9.56x |
| 2025-10-30 | 9.86x |
| 2025-10-29 | 9.76x |
| 2025-10-28 | 10.12x |
| 2025-10-27 | 10.33x |
| 2025-10-24 | 10.19x |
| 2025-10-23 | 10.06x |
| 2025-10-22 | 9.35x |
| 2025-10-21 | 9.39x |
| 2025-10-20 | 9.38x |
| 2025-10-17 | 9.20x |
| 2025-10-16 | 9.05x |
| 2025-10-15 | 8.82x |
| 2025-10-14 | 8.71x |
| 2025-10-13 | 8.75x |
| 2025-10-10 | 8.41x |
| 2025-10-09 | 8.85x |
| 2025-10-08 | 9.24x |
| 2025-10-07 | 9.02x |
| 2025-10-06 | 8.92x |
| 2025-10-03 | 9.05x |
| 2025-10-02 | 9.08x |
| 2025-10-01 | 8.99x |
| 2025-09-30 | 8.79x |
| 2025-09-29 | 8.82x |
| 2025-09-26 | 8.92x |
| 2025-09-25 | 8.92x |
| 2025-09-24 | 9.19x |
| 2025-09-23 | 9.42x |
| 2025-09-22 | 9.78x |
| 2025-09-19 | 9.56x |
| 2025-09-18 | 9.47x |
| 2025-09-17 | 9.37x |
| 2025-09-16 | 9.32x |
| 2025-09-15 | 8.95x |
| 2025-09-12 | 8.97x |
| 2025-09-11 | 9.15x |
| 2025-09-10 | 8.45x |
| 2025-09-09 | 8.49x |
| 2025-09-08 | 8.28x |
| 2025-09-05 | 8.16x |
| 2025-09-04 | 8.17x |
| 2025-09-03 | 8.39x |
| 2025-09-02 | 8.74x |
| 2025-08-29 | 9.00x |
| 2025-08-28 | 9.13x |
| 2025-08-27 | 9.18x |
| 2025-08-26 | 9.02x |
| 2025-08-25 | 9.00x |
| 2025-08-22 | 9.37x |
| 2025-08-21 | 9.29x |
| 2025-08-20 | 9.53x |
| 2025-08-19 | 9.59x |
| 2025-08-18 | 9.81x |
| 2025-08-15 | 9.96x |
| 2025-08-14 | 10.13x |
| 2025-08-13 | 10.30x |
| 2025-08-12 | 10.23x |
| 2025-08-11 | 9.94x |
| 2025-08-08 | 8.96x |
| 2025-08-07 | 9.08x |
| 2025-08-06 | 9.29x |
| 2025-08-05 | 9.82x |
| 2025-08-04 | 10.03x |
| 2025-08-01 | 9.43x |
| 2025-07-31 | 9.30x |
| 2025-07-30 | 8.44x |
| 2025-07-29 | 9.00x |
| 2025-07-28 | 9.03x |
| 2025-07-25 | 9.27x |
| 2025-07-24 | 9.16x |
| 2025-07-23 | 9.42x |
| 2025-07-22 | 9.06x |
| 2025-07-21 | 8.90x |
| 2025-07-18 | 9.41x |
| 2025-07-17 | 9.63x |
| 2025-07-16 | 9.69x |
| 2025-07-15 | 9.88x |
| 2025-07-14 | 9.98x |
| 2025-07-11 | 9.62x |
| 2025-07-10 | 10.63x |
| 2025-07-09 | 10.76x |
| 2025-07-08 | 10.62x |
| 2025-07-07 | 10.66x |
| 2025-07-03 | 10.99x |
| 2025-07-02 | 10.87x |
| 2025-07-01 | 11.06x |
| 2025-06-30 | 11.38x |
| 2025-06-27 | 11.17x |
| 2025-06-26 | 11.06x |
| 2025-06-25 | 10.94x |
| 2025-06-24 | 11.27x |
| 2025-06-23 | 10.85x |
| 2025-06-20 | 10.53x |
| 2025-06-18 | 10.56x |
| 2025-06-17 | 11.56x |
| 2025-06-16 | 12.03x |
| 2025-06-13 | 12.11x |
| 2025-06-12 | 12.12x |
| 2025-06-11 | 12.11x |
| 2025-06-10 | 11.94x |
| 2025-06-09 | 11.82x |
| 2025-06-06 | 11.79x |
Showing the most recent 260 of 1,793 data points. The chart above shows the full history.
Related Metrics
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein